Loading stock data…
$8.02-0.17 (-2.08%)
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
Palatin Technologies, Inc. in the Healthcare sector is trading at $8.19 with a market capitalization of $21M. Wall Street consensus targets $53.50 (3 analysts), implying a +553.2% move over the next 12 months. The stock is currently near its 52-week low of $5.61, remaining 44.4% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.92M↑ | $116,036↓ | $8.85M | $0 | $0 |
| Gross Profit | — | — | — | $0 | $0 |
| Operating Income | -$1.58M↑ | -$7.33M↓ | $4.66M↑ | -$4.60M↑ | -$5.23M |
| Net Income | -$1.43M↑ | -$7.26M↓ | $4.68M↑ | -$2.23M↑ | -$4.81M |
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonis...